reviewed april 2026|next review october 2026|88 physicians psi has verified|250 published studies
Bimagrumab
Bimagrumab is a human monoclonal antibody blocking the activin type II receptor (ActRII) that produced simultaneous fat loss and muscle gain in a Phase II obesity trial, with 62 published human studies making it the most clinically advanced myostatin pathway inhibitor.
Evidence landscape: 250 published studies
250 published items. 62 human studies and 120 animal studies.
- 62 Human
- 120 Animal
- 18 Reviews
- 50 Other research
Not FDA-approved. Phase II completed for obesity and type 2 diabetes. Phase II/III completed for inclusion body myositis (IBM). Clinical development is active. No approved myostatin pathway inhibitor exists.
Investigational only. Available only through clinical trials. Not available through specialty pharmacies or research suppliers.
Bimagrumab is a human monoclonal antibody targeting the activin type II receptor (ActRII). By blocking myostatin and activin signaling, it simultaneously increases lean muscle mass and reduces fat mass. 62 published human studies make it the most clinically advanced myostatin pathway inhibitor.
PSI Assessment
Bimagrumab produced a result in Phase II that no approved obesity medication has achieved: simultaneous fat loss and muscle gain. In obese type 2 diabetes patients, a 48-week trial showed 20% fat mass reduction with 3.6% lean mass gain. Every approved anti-obesity drug, including the GLP-1 receptor agonists, causes significant lean mass loss alongside fat loss (30-40% of total weight lost is lean tissue with semaglutide). Bimagrumab reversed this equation. The Phase II/III inclusion body myositis (IBM) trial told a more complicated story: muscle mass increased but functional endpoints did not improve, highlighting the gap between biological activity and clinical benefit. With 62 published human studies, bimagrumab has the deepest clinical dataset of any myostatin pathway inhibitor. Whether it reaches FDA approval for any indication remains an open question.
Simultaneous fat loss and muscle gain in Phase II obesity trial. 62 human studies. Phase II/III IBM trial failed its primary endpoint despite biological activity.
The mechanism is monoclonal antibody blockade of the activin type II receptor (ActRII), preventing myostatin and activin from signaling muscle cells to limit growth. By blocking the receptor rather than individual ligands, bimagrumab inhibits the entire growth-limiting pathway. The obesity Phase II result was notable because participants simultaneously lost fat mass and gained lean muscle mass, a combination that no approved anti-obesity medication achieves. The inclusion body myositis (IBM) trial showed increased muscle mass but no improvement in functional outcomes, highlighting the gap between biological activity and clinical benefit.
What the evidence supports
Phase II obesity trial demonstrated simultaneous fat loss and lean muscle gain, a combination no approved obesity medication achieves. Phase II/III IBM trial showed increased muscle mass (biological activity confirmed). 62 human studies provide the deepest clinical dataset of any myostatin pathway inhibitor. The anti-ActRII mechanism is pharmacologically validated.
What is not yet established
Whether the simultaneous fat loss and muscle gain replicates in Phase III obesity trials. Why increased muscle mass in IBM did not translate to functional improvement. Whether bimagrumab will achieve FDA approval for any indication. Long-term safety of sustained ActRII blockade.
Research Evidence
The findings below cover the Phase II obesity data, the IBM trial results, and the broader clinical dataset across 62 human studies.
Evidence by condition
Evidence dimensions available for each condition Bimagrumab has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Obesity / Body Composition | ||||
| Inclusion Body Myositis (IBM) | ||||
| Sarcopenia | ||||
| Muscle Wasting |
Phase II trial in obese type 2 diabetes patients demonstrated 20% fat mass reduction with simultaneous 3.6% lean mass gain over 48 weeks. Metabolic markers including HbA1c also improved. This dual body composition effect has not been replicated by any approved medication.
This is Phase II data. Phase III confirmation is needed before any conclusions about clinical utility. The comparison to GLP-1 drugs is pharmacologically valid but has not been tested in a head-to-head trial.
62 Human|120 Animal|18 Reviews
View all 250 indexed studiesHow Bimagrumab Works
Bimagrumab is a human monoclonal antibody targeting activin type II receptors (ActRIIA and ActRIIB). By blocking myostatin and activin signaling through ActRII, it prevents Smad2/3 activation in skeletal muscle, promoting myofiber hypertrophy and reducing adipogenesis.
Myostatin is the body's natural muscle growth brake. It tells muscles to stop growing once they are big enough. Bimagrumab blocks the receptor that myostatin uses, effectively releasing the brake. Without the brake signal, muscles grow and the body shifts energy toward building muscle rather than storing fat.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Bimagrumab is a human monoclonal antibody targeting ActRII (activin type II receptor). By blocking activin A and myostatin signaling through ActRII, it prevents Smad2/3 activation in skeletal muscle, promoting myofiber hypertrophy and reducing adipogenesis.
What is Bimagrumab being studied for?
Researchers are studying Bimagrumab across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Bimagrumab overall. This means a compound can have human studies for one condition but only animal data for another.
Obesity / Body Composition
·Human TrialsPhase II trial in obese type 2 diabetes patients showed 20% fat mass reduction with simultaneous 3.6% lean mass gain over 48 weeks. A dual body composition effect no approved obesity medication achieves.
Limitations: Phase II data only. Phase III confirmation needed. Whether the effects are sustained long-term is unknown. Combination with GLP-1 drugs has not been studied.
Inclusion Body Myositis (IBM)
·Human TrialsPhase II/III trial showed increased muscle mass in IBM patients. However, the primary functional endpoint was not met. This highlighted the gap between biological activity and clinical benefit.
Limitations: Primary endpoint failed. Whether increased muscle mass can eventually translate to functional improvement with modified dosing or combination approaches is unknown.
Sarcopenia
·Animal StudiesPhase II data in sarcopenia showed increased thigh muscle volume and lean body mass. Functional improvement (strength, mobility) was less consistent than the body composition changes.
Limitations: Whether increased muscle mass translates to meaningful functional improvement in elderly patients remains debated.
Muscle Wasting
·Animal StudiesThe ActRII blockade mechanism is validated for increasing lean mass across multiple patient populations. Applications in COPD-related muscle loss and cancer cachexia have been explored.
Limitations: Functional endpoints have been harder to achieve than body composition endpoints across all indications studied.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Phase II completed for obesity/T2D. Phase II/III completed for IBM. Clinical development is active.
Availability: Investigational only. Available through clinical trials. Not commercially available through any channel.
Class context: Bimagrumab is a monoclonal antibody, not a peptide. Muscle-related adverse events (fasciculations, cramps) reported. Transient FSH/LH elevations from activin blockade affecting the reproductive axis. Mild diarrhea and skin reactions observed.
Phase II data shows generally tolerable safety. Muscle-related adverse events (involuntary muscle contractions, muscle pain) were reported. Transient elevations in FSH and LH occurred due to activin blockade affecting the reproductive axis. Mild diarrhea and skin reactions were observed. Longer-term safety data from Phase III is needed.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Bimagrumab discussion.
Comparison and Related Research
Bimagrumab sits at the intersection of the myostatin pathway inhibitor field and the obesity pharmacology space. Both contexts are relevant.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase II trial demonstrating that bimagrumab produced a notable dual effect in adults with type 2 diabetes and obesity: significant reduction in fat mass combined with increase in lean mass. Participants lost an average of 20.5% of their fat mass over 48 weeks, a result that generated substantial interest in the anti-activin receptor II antibody approach to body composition.Heymsfield SB et al., 2021 in JAMA Netw Open. View on PubMed
- 2.Phase II proof-of-concept trial evaluating bimagrumab in patients with sporadic inclusion body myositis (IBM), a progressive muscle disease. The study demonstrated that blocking activin type II receptors produced measurable increases in thigh muscle volume, providing clinical validation of the myostatin/activin signaling pathway as a therapeutic target.Amato AA et al., 2014 in Neurology. View on PubMed
- 3.Controlled study examining whether bimagrumab could counteract muscle loss caused by leg immobilization in healthy men. The study used casting-induced atrophy as a model for disuse muscle wasting and measured recovery of thigh muscle volume and composition following treatment.Rooks DS et al., 2017 in J Cachexia Sarcopenia Muscle. View on PubMed
- 4.Phase II study in overweight and obese individuals with insulin resistance. Bimagrumab treatment led to significant reductions in fat mass with simultaneous increases in lean mass, and also improved insulin sensitivity. These body composition changes occurred without intentional dietary modification.Garito T et al., 2018 in Diabetes Obes Metab. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.